This data collection study aims to describe and compare the outcomes of Mpox on people living with HIV (PLHIV) and HIV-negative individuals who are on pre-exposure prophylaxis (PrEP). The study also aims to identify risk factors for specific Mpox outcomes.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Severe Mpox Lesions
Timeframe: From date of disease onset (first symptom) until date of peak number of lesions and sites recorded (up to 3 months)
Clinical Complications Associated With Mpox
Timeframe: From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months)
Number of Hospitalisation Events
Timeframe: From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months)
Death
Timeframe: From date of disease onset (first symptom) until date of death related to Mpox (up to 3 months)
Differences in Mpox Lesion Severity (the Clinical Manifestation) in PLWHIV and PrEP Users
Timeframe: From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months)
Differences in the Clinical Manifestation of Mpox in PLWHIV and PrEP Users by Site of Lesions
Timeframe: From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months)
Differences in the Clinical Manifestation of Mpox in PLWHIV and PrEP Users by Severity Indicators
Timeframe: From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months)
Differences in the NEWS2 Score ≥5 (Severity Indicator) in PLWHIV and PrEP Users With Mpox
Timeframe: From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months)
Differences in the Drug Treatments of Mpox in PLWHIV and PrEP Users
Timeframe: From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months)
Differences in the Drug Treatments for Complications of Mpox in PLWHIV and PrEP Users
Timeframe: From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months)
Differences in the First Symptom at Onset of Mpox in PLWHIV and PrEP Users
Timeframe: Mpox onset
Mpox Transmission
Timeframe: Mpox onset
Mpox Transmission Characteristics
Timeframe: Mpox onset
Risk Factors for Mpox Outcomes
Timeframe: From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months)
Risk Factors for Mpox Outcomes for PLWHIV
Timeframe: From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death(up to 3 months)